Her-2/neu oncogene expression in prostate carcinoma: Evaluation of gene amplification by FISH method

KAUGUSUZ, Gülşah; SERTÇELİK, Ayşe; SAK, Dizbay Serpil; KUZU, ISINSU; Baltacı, Sümer; KANKAYA, Duygu

Her-2/neu oncogene expression in prostate carcinoma: Evaluation of gene amplification by FISH method

Duygu KANKAYA, (Ankara Üniversitesi, Tıp Fakültesi, Patoloji Anabilim Dalı, Ankara, Türkiye)

Ayşe SERTÇELİK, (Ankara Üniversitesi, Tıp Fakültesi, Patoloji Anabilim Dalı, Ankara, Türkiye)

Gülşah KAUGUSUZ, (Ankara Üniversitesi, Tıp Fakültesi, Patoloji Anabilim Dalı, Ankara, Türkiye)

Işınsu KUZU, (Ankara Üniversitesi, Tıp Fakültesi, Patoloji Anabilim Dalı, Ankara, Türkiye)

Dizbay Serpil SAK, (Ankara Üniversitesi, Tıp Fakültesi, Patoloji Anabilim Dalı, Ankara, Türkiye)

Sümer BALTACI (Ankara Üniversitesi, Tıp Fakültesi, Üroloji Anabilim Dalı, Ankara, Türkiye)

Türk Patoloji Dergisi

4 0

Yıl: 2008 Cilt: 24 Sayı: 2 Sayfa Aralığı: 76 - 83 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Her-2/neu oncogene expression in prostate carcinoma: Evaluation of gene amplification by FISH method

Öz:

Prostat kanserinin biyolojik davranışındaki değişkenlik ve prognostik belirleyicilerin yetersizliği, hastaların takip ve tedavisinde zorluklara neden olmaktadır. Yetmiş dört prostat kanseri olgusunu içeren çalışmamızda, Her-2/neu onkogeninin kanser başlangıcı ve ilerlemesindeki rolünü araştırdık. Doku “array” bloğu hazırlandı ve aşırı Her-2/neu protein ekspresyonu karsinom, düşük ve yüksek dereceli intraepitelyal neoplazi ve benign prostat hiperplazisi alanlarında değerlendirildi. Elli altı karsinom olgusunda flöresan in-situ hibridizasyon (FISH) yöntemiyle Her-2/neu gen amplifikasyonu araştırıldı. Her-2/neu proteini sitoplazmik ve membranöz ekspresyon gösterdi. Ekspresyonun benign prostat hiperplazisi alanlarından prostatik intraepitelyal neoplazi alanlarına gidildikçe artış gösterdiği ve karsinom alanlarında en yüksek düzeye ulaştığı görüldü. Prostat kanseri vakalarında Her-2/neu ekspresyon oranı %72.97 iken, gen amplifikasyon oranı %4.05 olarak tespit edildi. Kromozom 17'de polizomi veya başka herhangi bir anomali izlenmedi. Her-2/neu protein ekspresyon ve gen amplifikasyon düzeyi ile Gleason skoru, tümör evresi gibi bilinen prognostik parametreler arasında herhangi bir ilişki izlenmedi. Ekspresyon ve amplifikasyon oranları arasındaki tutarsızlık, ekspresyonun gerçek bir gen amplifikasyonu dışı nedenlere bağlı olabileceğini düşündürdü. Büyük kısmını klinik lokalize prostat karsinomu olgularının oluşturduğu hasta grubunu içeren çalışmamızda sonuçlar, Her-2/neu onkogeninin klinik olarak lokalize evrede öneminin olmadığını düşündürmüş, ancak daha ileri evreler ve androjen bağımsız faza geçiş ile ilgili yorum yapılamamıştır.

Anahtar Kelime: İn situ hibridizasyon, floresan Gen amplifikasyonu Genler, erbB-2 İmmünohistokimya Prostat neoplazmları

Konular: Cerrahi

Prostat kanserinde Her-2/neu onkogen ekspresyonu: Gen amplifikasyonunun FISH yöntemiyle değerlendirilmesi

Öz:

The variability in the biological behaviour of prostate cancer and the inadequacy of markers used for assessing prognosis cause difficulties in the management of patients. We conducted a study of 74 prostate carcinomas to identify the significance of Her-2/neu oncogene in the initiation and progression of prostate carcinoma. Tissue array blocks were constructed and overexpression of Her-2/neu protein was assessed in areas of carcinoma, low and high grade intraepithelial neoplasia and benign prostate hyperplasia by immunohistochemistry. Flourescence in-situ hybridization (FISH) method was used to investigate Her-2/neu gene amplification in areas of carcinoma of 56 cases. Her-2/neu protein was expressed in a cytoplasmic/membranous manner. The expression rate significantly increased from areas of benign prostate hyperplasia to prostatic intraepithelial neoplasia and reached the highest degree in areas of carcinoma. Her-2/neu overexpression was observed in 72.97% of prostate carcinomas while gene amplification was present in 4.05% of the cases. Polisomy or any other anomaly involving chromosome 17 was not detected. There was no relationship between the ratio of Her-2/neu protein expression or gene amplification and known prognostic parameters as Gleason grade, and stage of the tumor. The discordance between the expression and amplification rates suggested that expression may be the cause of some other factors rather than true gene amplification. According to the results of the present study involving mostly the clinically localized prostate carcinomas, it can be suggested that Her-2/neu oncogene does not seem to have any role in clinically localized prostate carcinoma, but no assessment could be made for advanced stage carcinomas and the progression to androgen independent disease.

Anahtar Kelime: Genes, erbB-2 Immunohistochemistry Prostatic Neoplasms In Situ Hybridization, Fluorescence Gene Amplification

Konular: Cerrahi

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1) Hung MC, Schechter AL, Chevray PY, Stem DF, Weinberg RA. Molecular cloning of the neu gene: Absence of gross structural alteration in oncogenic alleles. Proc Natl Acad Sci USA 1986; 83:261-264.
2) Hynes NE, Stern DF. The biology of erbB-2/neu: Her- 2 and its role in cancer. Biochem Biophys Acta Rev Cancer 1994; 1198:165-184.
3) Press MF, Bernstein L, Thomas PA, Zhou JY, Ma Y, Hung G, et al. Her-2/neu gene amplification characterized by flourescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997;15: 2894-2904.
4) Saffari B, Jones LA, el-Naggar A, Felix JC, George J, Press MF. Amplification and overexpression of Her- 2/neu (c-erbB2) in endometrial cancers: correlation with overall survival. Cancer Res 1995;55: 5693-5698.
5) Ranzani GN, Pellegata NS, Previdere C, Saragoni A, Vio A, Maltoni M, Amadori D. Heterogeneous protooncogene amplification correlates with tumor progression and presence of metastasis in gastric cancer patients. Cancer Res 1990; 50: 7811-7814.
6) Press MF, Pike MC, Hung G, Zhou JY, Ma Y, George J, et al. Amplification and overexpression of Her-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res 1994; 54: 5675-5682.
7) Zhau HE, Zhang X, von Eschenbach AC, Scorsone K, Babaian RJ, Ro JY, Hung MC. Amplification and expression of the c-erbB2/neu proto-oncogene in human bladder cancer. Mol Carcinogen 1990;3:254-257.
8) Visokarpi T, Kallioniemi OP, Koivula T, Harvey J, Isola J. Expression of epidermal growth factor receptor and erbB2 (Her2/neu) oncoprotein in prostatic carcinomas. Mod Pathol 1992; 5: 643-648.
9) Sadasivan R, Morgan R, Jenning S, Austenfeld M, Van Veldhuizen P, Stephens R, Noble M. Overexpression of HER-2/neu may be an indicator of poor prognosis in prostate cancer. J Urol 1993; 1993:126-131.
10) Cohen RJ, Cooper K, Haffejee Z, Robinson E, Becker PJ. Immunohistochemical detection of oncogene proteins and neuroendocrine differentiation in different stages of protate cancer. Pathology 1995; 27: 229-232.
11) Lara PN Jr, Meyers FJ, Gray CR, Edwards RG, Gumerlock PH, Kauderer C, et al. HER-2 / neu is overexpressed infrequently in patients with prostate carcinoma. Results from the California Cancer Consortium Screening Trial. Cancer 2002 May 15; 94: 2584-2589.
12) Ross JS, Nazeer T, Church K, Amato C, Figge H, Rifkin MD, et al. Contribution of HER-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma and metastasis. Cancer 1993; 72: 3020-3028.
13) Epstein JI, Amin M, Boccon-Gibod L, Egevad L, Humphrey PA, Mikuz G, et al. Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand J Urol Nephrol Suppl. 2005;216:34-63.
14) San Miguel Fraile P, Dos Santos JE, Pélaez Boismorand E, Ortiz Rey JA, Iglesias Rodríguez B, Cambronero Santos J, et al. Expression of the cerbB-2 (HER- 2/neu) oncoprotein in prostatic adenocarcinoma. Actas Urol Esp 2005; 29:64-69.
15) Ware JL, Maygarden SJ, Koontz WW, Strom SC. Immunohistochemical detection of c-erbB-2 protein in human benign and neoplastic prostate. Hum Pathol 1991; 22: 254-258.
16) Sanchez KM, Sweeney CJ, Mass R, Koch MO, Eckert GJ, Geary WA, et al. Evaluation of HER-2/neu expression in prostatic adenocarcinoma: A request for a standardized, organ spesific methodology. Cancer 2002; 95:1650-1655.
17) Zhau HE, Wan DS, Zhou J, Miller GJ, et al. Expression of c-erbB2/ neu protooncogene in human prostatic cancer tissues and cell lines. Mol Carcinog 1992; 5:320-327.
18) Kameda T, Yasui W, Yoshida K, Tsujino T, Nakayama H, Ito M, et al. Expression of ERBB2 in human gastric carcinomas: relationship between p185ERBB2 expression and the gene amplification. Cancer Res 1990; 50: 8002 8009.
19) Gu K, Mes-Masson A, Gauthier J, Saad F. Overexpression of Her-2/neu in human prostate cancer and benign hyperplasia. Cancer Letters 1996; 99: 185 189.
20) Ross JS, Sheehan CE, Hayner-Buchan AM, Ambros RA, Kallakury BV, Kaufman RP Jr, et al. Prognostic significance of Her-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma. Cancer 1997; 79: 2162-2170.
21) Ross JS, Sheehan C, Hayner-Buchan AM, Ambros RA, Kallakury BV, Kaufman R, et al. Her-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization. Hum Pathol 1997;28: 827-833.
22) Kallakury BV, Sheehan CE, Ambros RA, Fisher HA, Kaufman RP Jr, Muraca PJ, Ross JS. Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and Her-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas. J Clin Oncol 1998;16:1302-1309.
23) Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC, et al. Survey of gene amplifications during prostate cancer progression by high throughput fluorescence in situ hybridization on tissue microarrays. Cancer Res 1999;59:803-806.
24) Oxley JD, Winkler MH, Gillatt DA, and Peat DS. Her- 2/neu oncogene amplification in clinically localised prostate cancer. J Clin Pathol 2002; 55:118-120.
25) Arai Y, Yoshiki T, Yoshida O. C-erbB2 oncoprotein: a potential biomarker of advanced prostate cancer. Prostate 1997; 30: 195-201.
26) Morote J, de Torres I, Caceres C, Vallejo C, Schwartz S Jr, Raventos J. Prognostic value of immunohistochemical expression of the c-erbB2 oncoprotein in metastatic prostate cancer. Int J Cancer 1999; 84:421-425.
27) Craft N, Shostak Y, Carey M, Sawyers C: A mechanism for hormone independent prostate cancer through modulation of androgen receptor signaling by the Her2/neu tyrosine kinase. Nat Med 1999; 5:280-285.
28) Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G, et al: Her-2/neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 2000; 92: 1918-1925.
29) Montironi R, Mazzucchelli R. HER-2 expression and gene amplification in high-grade PIN and prostate cancer. Arch Ital Urol Androl 2006;78:135-139.
30) Agus DB, Bunn PA Jr, Franklin W, Garcia M, Ozols RF. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. Semin Oncol 2000; 27(6 Suppl 11):53-63; discussion 92-100.
31) Ziada A, Barqawi A, Glode LM, Varella-Garcia M, Crighton F, Majeski S, et al. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 2004; 60:332-337.

APA	KANKAYA D, SERTÇELİK A, KAUGUSUZ G, KUZU I, SAK D, Baltacı S (2008). Her-2/neu oncogene expression in prostate carcinoma: Evaluation of gene amplification by FISH method. , 76 - 83.
Chicago	KANKAYA Duygu,SERTÇELİK Ayşe,KAUGUSUZ Gülşah,KUZU ISINSU,SAK Dizbay Serpil,Baltacı Sümer Her-2/neu oncogene expression in prostate carcinoma: Evaluation of gene amplification by FISH method. (2008): 76 - 83.
MLA	KANKAYA Duygu,SERTÇELİK Ayşe,KAUGUSUZ Gülşah,KUZU ISINSU,SAK Dizbay Serpil,Baltacı Sümer Her-2/neu oncogene expression in prostate carcinoma: Evaluation of gene amplification by FISH method. , 2008, ss.76 - 83.
AMA	KANKAYA D,SERTÇELİK A,KAUGUSUZ G,KUZU I,SAK D,Baltacı S Her-2/neu oncogene expression in prostate carcinoma: Evaluation of gene amplification by FISH method. . 2008; 76 - 83.
Vancouver	KANKAYA D,SERTÇELİK A,KAUGUSUZ G,KUZU I,SAK D,Baltacı S Her-2/neu oncogene expression in prostate carcinoma: Evaluation of gene amplification by FISH method. . 2008; 76 - 83.
IEEE	KANKAYA D,SERTÇELİK A,KAUGUSUZ G,KUZU I,SAK D,Baltacı S "Her-2/neu oncogene expression in prostate carcinoma: Evaluation of gene amplification by FISH method." , ss.76 - 83, 2008.
ISNAD	KANKAYA, Duygu vd. "Her-2/neu oncogene expression in prostate carcinoma: Evaluation of gene amplification by FISH method". (2008), 76-83.

APA	KANKAYA D, SERTÇELİK A, KAUGUSUZ G, KUZU I, SAK D, Baltacı S (2008). Her-2/neu oncogene expression in prostate carcinoma: Evaluation of gene amplification by FISH method. Türk Patoloji Dergisi, 24(2), 76 - 83.
Chicago	KANKAYA Duygu,SERTÇELİK Ayşe,KAUGUSUZ Gülşah,KUZU ISINSU,SAK Dizbay Serpil,Baltacı Sümer Her-2/neu oncogene expression in prostate carcinoma: Evaluation of gene amplification by FISH method. Türk Patoloji Dergisi 24, no.2 (2008): 76 - 83.
MLA	KANKAYA Duygu,SERTÇELİK Ayşe,KAUGUSUZ Gülşah,KUZU ISINSU,SAK Dizbay Serpil,Baltacı Sümer Her-2/neu oncogene expression in prostate carcinoma: Evaluation of gene amplification by FISH method. Türk Patoloji Dergisi, vol.24, no.2, 2008, ss.76 - 83.
AMA	KANKAYA D,SERTÇELİK A,KAUGUSUZ G,KUZU I,SAK D,Baltacı S Her-2/neu oncogene expression in prostate carcinoma: Evaluation of gene amplification by FISH method. Türk Patoloji Dergisi. 2008; 24(2): 76 - 83.
Vancouver	KANKAYA D,SERTÇELİK A,KAUGUSUZ G,KUZU I,SAK D,Baltacı S Her-2/neu oncogene expression in prostate carcinoma: Evaluation of gene amplification by FISH method. Türk Patoloji Dergisi. 2008; 24(2): 76 - 83.
IEEE	KANKAYA D,SERTÇELİK A,KAUGUSUZ G,KUZU I,SAK D,Baltacı S "Her-2/neu oncogene expression in prostate carcinoma: Evaluation of gene amplification by FISH method." Türk Patoloji Dergisi, 24, ss.76 - 83, 2008.
ISNAD	KANKAYA, Duygu vd. "Her-2/neu oncogene expression in prostate carcinoma: Evaluation of gene amplification by FISH method". Türk Patoloji Dergisi 24/2 (2008), 76-83.